Targeting HMGB1 inhibits ovarian cancer growth and metastasis by lentivirus-mediated RNA interference (Q39396939)

Dataset for "Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine"

11 September 2017

2 references

Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine

title

Targeting HMGB1 inhibits ovarian cancer growth and metastasis by lentivirus-mediated RNA interference (English)

1 reference

11 September 2017

1 reference

1 reference

Jie Chen

1

1 reference

11 September 2017

Xiaoyan Liu

series ordinal

2

1 reference

11 September 2017

Jie Zhang

series ordinal

3

1 reference

11 September 2017

Yueran Zhao

series ordinal

4

1 reference

11 September 2017

1 November 2012

1 reference

Journal of Cellular Physiology

11 September 2017

1 reference

11 September 2017

227

1 reference

11 September 2017

11

1 reference

11 September 2017

3629-3638

1 reference

Prognostic value of HMGB1 overexpression in resectable gastric adenocarcinomas

11 September 2017

1 reference

The biology of ovarian cancer: new opportunities for translation

21 January 2018

1 reference

Identification of the core-histone-binding domains of HMG1 and HMG2

21 January 2018

1 reference

Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion

21 January 2018

1 reference

HMGB1: a two-headed signal regulating tumor progression and immunity

21 January 2018

1 reference

A perspective on cancer cell metastasis

21 January 2018

1 reference

Integrin beta3 down-regulates invasive features of ovarian cancer cells in SKOV3 cell subclones

21 January 2018

1 reference

Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer

21 January 2018

1 reference

Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products

21 January 2018

1 reference

Masquerader: high mobility group box-1 and cancer

21 January 2018

1 reference

HMGB1, a potent proinflammatory cytokine in sepsis

21 January 2018

1 reference

Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development.

21 January 2018

1 reference

Cytolytic cells induce HMGB1 release from melanoma cell lines

21 January 2018

1 reference

21 January 2018

Cancer statistics, 2010

1 reference

The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy

21 January 2018

1 reference

Crosstalk between calcium, amyloid beta and the receptor for advanced glycation endproducts in Alzheimer's disease

21 January 2018

1 reference

High-mobility group box 1-mediated matrix metalloproteinase-9 expression in non-small cell lung cancer contributes to tumor cell invasiveness

21 January 2018

1 reference

Proliferating cell nuclear antigen: a proteomics view

21 January 2018

1 reference

RAGE and cardiovascular disease

21 January 2018

1 reference

Serum high mobility group box protein 1 as a clinical marker for non-small cell lung cancer.

21 January 2018

1 reference

Clinical value of serum HMGB1 levels in early detection of recurrent squamous cell carcinoma of uterine cervix: comparison with serum SCCA, CYFRA21-1, and CEA levels

21 January 2018

1 reference

HMGB1 and RAGE in inflammation and cancer

21 January 2018

1 reference

Hypoxia-increased RAGE and P2X7R expression regulates tumor cell invasion through phosphorylation of Erk1/2 and Akt and nuclear translocation of NF-{kappa}B.

21 January 2018

1 reference

High-mobility group box 1 and cancer

21 January 2018

1 reference

A human placental cDNA clone that encodes nonhistone chromosomal protein HMG-1

21 January 2018

1 reference

Increased expression of high mobility group box 1 (HMGB1) is associated with progression and poor prognosis in human nasopharyngeal carcinoma.

21 January 2018

1 reference

Targeting HMGB1 in inflammation

21 January 2018

1 reference

Up-regulated autophagy by endogenous high mobility group box-1 promotes chemoresistance in leukemia cells.

21 January 2018

1 reference

Overexpression of high-mobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma

21 January 2018

1 reference

Blockade of RAGE–amphoterin signalling suppresses tumour growth and metastases

21 January 2018

1 reference

Long-term results and prognostic factors in patients with epithelial ovarian cancer

21 January 2018

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.24069

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.24069

HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.24069

New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.24069

The role of cyclin D1 expression and patient's survival in non-small-cell lung cancer: a systematic review with meta-analysis

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.24069

Effect of HMGB1 silencing on cell proliferation, invasion and apoptosis of MGC-803 gastric cancer cells

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.24069

Identifiers

DOI

10.1002/JCP.24069

1 reference

11 September 2017

1 reference